ACVR2A and pulmonary arterial hypertension: ActRIIA-Fc functions by sequestering multiple ligands of the TGF-β superfamily, including Activins, Mstn, GDF-11, and select BMPs, and was recently approved by the FDA for the treatment of pulmonary arterial hypertension in adults (NCT04576988).